San Ramon, California-based The Cooper Companies, Inc. (COO) develops, manufactures, and markets contact lens wearers. Valued at a market cap of $14.8 billion, the company also focuses on family and women's health care, providing fertility products and services, medical devices, contraception, and cryostorage to health care professionals and patients. It is scheduled to announce its fiscal Q3 earnings for 2025 after the market closes on Wednesday, Aug. 27.

Before this event, analysts project this vision and women’s healthcare company to report a profit of $1.06 per share, up 10.4% from $0.96 per share in the year-ago quarter. The company has met or surpassed Wall Street’s bottom-line estimates in each of the last four quarters. Its earnings of $0.96 per share in the previous quarter outpaced the consensus estimates by 3.2%. 

For the full year, analysts expect COO to report EPS of $4.06, up 10% from $3.69 per share in fiscal 2024. Furthermore, its EPS is expected to grow 9.9% year-over-year to $4.46 in fiscal 2026. 

Shares of COO have declined 19.8% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 17.3% uptick and the Health Care Select Sector SPDR Fund’s (XLV) 9.4% drop over the same time frame.

Despite delivering better-than-expected Q2 results on May 29, shares of COO plunged 14.6% in the following trading session. Due to growth in both of its reportable segments, the company’s overall revenue improved 6.3% year-over-year to $1 billion, exceeding consensus expectations. Moreover, its adjusted EPS of $0.96 advanced 12.9% from the year-ago quarter, topping analyst estimates by 3.2%. 

Wall Street analysts are moderately optimistic about COO’s stock, with an overall "Moderate Buy" rating. Among 15 analysts covering the stock, 10 recommend "Strong Buy," one indicates a "Moderate Buy," and four advise “Hold.” The mean price target for COO is $92.93, implying a 25.9% premium from the current levels.